retatrutide nejm 2023 obesity trial ly3437943 just posted the biggest weight-loss numbers ever recorded for a drug — 28.3% (≈70 lb) average in Phase 3, with 45% of people hitting 30%+ loss, territory once reserved for bariatric A Randomized, Controlled Trial of

The pattern: blockbusters now cycle faster: shorter dominance windows, steeper cliffs, quicker replacements

Posters were promotional, commemorative, collectible, and especially expressive

More hunger means overeating

Some of the key allegations in the Ozempic lawsuits include the following: Failure to warn and inadequate labeling: Lawsuits contain allegations that Novo Nordisk did not adequately warn Ozempic patients about some of the severe gastrointestinal and vision complications they might experience

Many adults across California are seeking medically guided programs that offer professional oversight without requiring frequent in-person visits

Retatrutide is a once-weekly injectable medication being studied for significant weight loss